Search results for "bladder"

showing 10 items of 628 documents

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?

2009

Abstract Background The aim of this study is to report on the impact of neuromodulation to the superior hypogastric plexus in patients with bladder atonia secondary to pelvic surgery. Methods In 4 consecutive patients with bladder atonia secondary to pelvic surgery, we performed a laparoscopic implantation of a neurostimulator—LION procedure—to the entire superior hypogastric plexus. Results Of the 4 reported patients, 3 are able to partially void or empty their bladder. Conclusions If the presented results could be obtained in further patients and maintained in long-term follow-up, the LION procedure to the superior hypogastric plexus could change the management of bladder function in pati…

Malemedicine.medical_treatmentEndometriosisurologic and male genital diseasesColonic DiseasesPostoperative ComplicationsMedicineLaparoscopyUrinary bladdermedicine.diagnostic_testProstatectomyHypogastric PlexusBladder atoniaEquipment DesignMiddle Agedfemale genital diseases and pregnancy complicationsPain IntractableBladder atonia; LION procedure; Superior hypogastric plexusmedicine.anatomical_structureFemaleSuperior hypogastric plexumedicine.symptomSuperior hypogastric plexusAdultmedicine.medical_specialtyUrinary BladderEndometriosisElectric Stimulation TherapyCauda equineHysterectomyPelvic Painmedicine.nerveSuperior hypogastric plexusHumansUrinary Bladder NeurogenicSpina bifidaProstatectomyHypogastric PlexusHysterectomybusiness.industryPelvic painProstatic Neoplasmsmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaEndometrial NeoplasmsSurgeryUrodynamicsRectal DiseasesLION procedureLaparoscopySurgeryNeurology (clinical)businessGenital Diseases FemaleFollow-Up Studies
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control stud…

2007

OBJECTIVES: To identify risk factors of carcinoma of the extrahepatic biliary tract in men. METHODS: Newly diagnosed and histologically confirmed patients, 35-70 years old, were interviewed between 1995 and 1997 in Denmark, Sweden, France, Germany and Italy. Population controls were frequency-matched by age and region. Adjusted odds ratios and 95%-confidence intervals were estimated by logistic regression. RESULTS: The analysis included 153 patients and 1421 controls. The participation proportion was 71% for patients and 61% for controls. Gallstone disease was corroborated as a risk factor for extrahepatic biliary tract carcinoma in men (odds ratio 2.49; 95% confidence interval 1.32-4.70), …

MaleobesityEtiologyEpidemiologyMedizinGastroenterologyBody Mass Index0302 clinical medicineBile Ducts ExtrahepaticCholelithiasisRisk FactorsMedicineAlcohol consumption2. Zero hungerBiliary tract neoplasmeducation.field_of_studySmokingGastroenterologyCase-control studyMenGallstonesMiddle Agedmedical history3. Good healthBiliary tract carcinomaBiliary Tract Neoplasms030220 oncology & carcinogenesisMedical history030211 gastroenterology & hepatologyGallbladder NeoplasmsepidemiologyGallbladder carcinomaAdultmedicine.medical_specialtyAmpulla of Vateralcohol consumptioncase-control studyetiologyPopulationCommon Bile Duct Neoplasmsmensmoking03 medical and health sciencesInternal medicinesmoking.HumansObesityRisk factoreducationLife StyleAgedbiliary tract carcinomaHepatologybusiness.industryCase-control studyOdds ratiomedicine.diseaseConfidence interval[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiegallbladder carcinomabusinessBody mass index
researchProduct

Transvestibular Urethrolysis.

2011

Bladder outlet obstruction with obstructive and irritative urinary symptoms may be a complication of surgery for female urinary incontinence. In presence of persistent symptoms the therapy is surgical and usually consists in an accurate urethrolysis. The way of approach is generally transvaginal. In this paper we propose and describe our experience with a transvestibular approach.From 1995 to 2009 18 women who had undergone anti-incontinence surgery (TVT 12 pts, TOT 3 pts, Burch retropubic colposuspension 3 pts) with obstruction and/or irritative symptoms underwent to a transvestibular urethrolysys. Five patients had urinary retention the other patients had post voiding residual urine100 ml…

Medical Records Systems ComputerizedUrinary Incontinence StressDissectionSuburethral tapeGeneral MedicineUrinary RetentionUrinary Bladder Neck ObstructionUrinary incontinence surgeryUrethrolysiTreatment OutcomePostoperative ComplicationsUrinary IncontinenceUrethraRetrospective StudieUrologic Surgical ProcedureVaginaHumansUrologic Surgical ProceduresFemalePostoperative ComplicationFemale urethraUrinary Incontinence StreRetrospective StudiesHuman
researchProduct

Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!

2015

An interesting series of 22 patients affected by severe systemic toxicity following bacillus Calmette-Guerin (BCG) intravesical adjuvant therapy for bladder cancer is presented in this issue of Inf...

Microbiology (medical)Malemedicine.medical_specialtyAntineoplastic AgentsGastroenterologySettore MED/24 - UrologiaInternal medicineparasitic diseasesmedicineAdjuvant therapyIntravesical bacillus Calmette-GuerinAnimalsHumansBacillus (shape)Mycobacterium bovisBladder cancerGeneral Immunology and Microbiologybiologybusiness.industryGeneral Medicinebiology.organism_classificationmedicine.diseaseMycobacterium bovisbladder cancer BCG toxicityInfectious DiseasesSystemic toxicityUrinary Bladder NeoplasmsBCG VaccinebusinessBCG vaccineInfectious diseases (London, England)
researchProduct

VALUTAZIONE CLINICA DELLA PROTEINA 22 DELLA MATRICE NUCLEARE COME MARCATORE TUMORALE NEL FOLLOW-UP DEI TUMORI A CELLULE TRANSIZIONALI DELLA VESCICA

2008

OBJECTIVES. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. MATERIALS AND METHODS. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 t…

NMP22 BIOMARKERS TRANSITIONAL CELL CARCINOMA OF THE BLADDERSettore MED/24 - Urologia
researchProduct